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Abstract  
 
Background. Chronic hepatitis C virus (HCV) infection affects about 71 million 
people worldwide. Nowadays, the standard therapy of chronic HCV infection is 
based on direct-acting antivirals (DAAs). DAAs are significantly more effective 
than pegylated interferon-alfa and ribavirin. Moreover, these drugs have a good 
tolerance and allow short treatment durations. It is common practice to monitor 
treatment efficacy with measurements of blood HCV viral load. However, we do 
not have clear recommendations for this monitoring, based on a model describing 
viral kinetics under DAA-based treatment. The additional usefulness of DAA 
concentration monitoring is uncertain.  
The aim of our study was to analyze whether HCV RNA profiles during DAA-
based therapies predict the final treatment outcome, to assess the adjunctive 
predictive value of drug concentration and liver function tests monitoring, and to 
describe clinical and laboratory characteristics of patients with post-treatment 
relapse.  
Methods. We conducted a retrospective observational study with chronic HCV 
infected patients. All included patients were ≥ 18 years old, treated with DAAs 
from 2013 to 2017 at CHUV (Lausanne, Switzerland). 
Results. We included in the study 202 patients (71% men, mean age 55 years). A 
sustained virologic response (SVR) was achieved by 193 (95.5%) patients, while 
9 (4.5%) patients had a post-treatment relapse. A previous history of 
hepatocellular carcinoma, HBV co-infection, and IL28B rs12979860 genotype 
CT were independent predictors of treatment failure. We did not find a 
relationship between therapy outcome and either HCV RNA, ALT or AST at 
baseline, at week 2, week 4, or at the end of treatment. The concentrations of 
sofosbuvir metabolite GS331007 and daclatasvir tended to be lower in patients 
with post-treatment relapse compared with patients with SVR, however the 
limited number of patients precludes any firm conclusion.  
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Conclusions. Beyond known pre-existing prognostic factors, confirmed in our 
study, there is no indication that the regular monitoring of HCV RNA, AST, and 
ALT during DAAs treatment could help to predict the sustained virologic 
response of HCV chronic infection to novel DAAs. The potential role of DAA 
concentration monitoring deserves to be evaluated in a larger study.  
 
Key words: Hepatitis C virus, direct-acting antivirals, sustained virologic 
response, HCV RNA, monitoring.     
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Background 
 
Chronic hepatitis C virus (HCV) infection affects about 71 million people 
worldwide [1, 2]. There are an estimated 1.75 million new HCV infections each 
year, with an incidence in European Region and the Eastern Mediterranean 
Region of about 62 cases per 100 000 population [3]. Switzerland has a prevalence 
of chronic HCV infection of about 0.5% (about 40 000 patients) [4], placing it 
among the regions with low prevalence (<1.5%) along with other countries in 
western and central Europe. In contrast, Central Africa and Central Asia have high 
prevalence (>3.5%) [5].  
About 55–85% of the usually asymptomatic acute HCV infections become 
chronic, with a 15–30% risk of developing cirrhosis within 20 years [6]. It should 
be noted that HCV is the cause of more than 400 000 deaths each year, an increase 
of 22% since 2000. Most of these deaths are related to the development of life‐
threatening complications such as cirrhosis (about 280 000 deaths) and 
hepatocellular carcinoma (HCC) (about 120 000 deaths) [6]. 
Until 2011, the standard treatment of chronic HCV infection had been a 
double therapy consisting of pegylated interferon-alfa (Peg-IFN) and ribavirin 
(RBV). But this treatment only yielded a sustained virologic response (SVR) rate 
of about 50-70% after 48 weeks [7]. The treatment of chronic HCV infection has 
been revolutionized by the introduction of direct-acting antivirals (DAAs) such 
as nucleoside and nucleotide NS5B polymerase inhibitors (sofosbuvir), NS5A 
inhibitors (daclatasvir, ledipasvir), NS3-4A protease inhibitors (grazoprevir), and 
non-nucleoside NS5B polymerase inhibitors (dasabuvir).  
In clinical trials DAAs allow the achievement of SVR in more than 90% of 
patients after 8-12 weeks of treatment [8]. DAAs are not only significantly more 
effective than Peg-IFN, they have a better tolerance, while permitting shorter 
treatment duration and oral administration [9].  
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Overall, the efficacy of DAA treatment is high. However, a certain 
proportion of patients has a risk of virological breakthrough or post-treatment 
relapse. To ensure treatment efficacy and patient compliance, international 
guidelines recommended a therapeutic monitoring based on measurements of 
HCV RNA levels in serum or plasma (with a lower limit of detection ≤15 IU/ml). 
Current guidelines recommend monitoring of quantitative HCV RNA at baseline, 
between week 2 and week 4, as well as at the end-of-treatment and 12 or 24 weeks 
after the end of the therapy (to assess SVR12 or SVR24, respectively) [8, 10, 11]. 
At the same time, the cost of DAA treatment is very high (for example, 12 weeks 
therapy with ledipasvir/sofosbuvir costs €40 000). Therefore, the monitoring of 
efficacy and compliance may be cost-effective.  
In clinical routine, HCV RNA measurements is not infrequently performed 
even more often. However, the results of trials are ambiguous towards an 
association of HCV RNA monitoring during treatment and treatment outcome. 
Actually, there are models describing the viral kinetics under DAA-based 
treatment, but their predictive value is questionable [12]. The adjunctive role of 
drug concentration monitoring and liver function tests monitoring is poorly 
supported by any evidence.  
The aims of our study were to analyze whether HCV RNA profiles during 
DAA therapies predict the final treatment outcome, to assess the adjunctive 
predictive value of drug concentration and liver function tests monitoring, and to 
describe clinical and laboratory characteristics of patients with post-treatment 
relapse.  
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Methods 
 
Study population 
 
We conducted a retrospective observational study in chronic HCV infected 
patients. All patients were ≥ 18 years old and treated for chronic HCV infection 
with DAAs from 2013 to 2017 at the CHUV (Lausanne, Switzerland). Clinical 
and laboratory data were obtained from paper medical records and CHUV 
databases of medical records (Soarian, Archimède, and Molis). We excluded 
patients who refused the reuse of their personal data, as well as patients with less 
than 3 determinations of HCV RNA level during the observational period.  
To select patients for the study, we first extracted data from the laboratory 
database Molis (patients with 3 or more available measurements of HCV RNA 
and liver function from 1 January 2013 to 31 August 2017). First, we selected 
only chronic HCV patients followed at the Service of Gastroenterology and 
Hepatology treated between 1 January 2013 and 31 August 2017 with one of the 
following combinations: sofosbuvir and daclatasvir, sofosbuvir and ledipasvir or 
sofosbuvir and simeprevir, with or without ribavirine. Secondly, among the 
patients listed in the Molis extraction, we looked for those having available 
plasma concentration results for sofosbuvir, its metabolite (GS331007), 
daclatasvir or ledipasvir. Inclusion and exclusion criteria were also checked. For 
all these patients we obtained completed clinical, histological, and laboratory data 
from paper medical records and databases (Soarian, Archimède, and Molis).  
This study was approved by the Commission cantonale d'éthique de la 
recherche sur l'être humain (CER-VD, project No 2017-01102).  
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2. Treatments 
 
We included in our study patients treated with DAAs (sofosbuvir, 
daclatasvir, ledipasvir, simeprevir), with or without ribavirin. Drug combinations 
and doses were defined by physicians based on patient characteristics and 
applicable guidelines at the time of treatment.  
 
3. Study assessments 
 
SVR was defined as undetectable HCV RNA 12 weeks after treatment 
completion [8, 10]. Post-treatment relapse was defined as confirmed HCV RNA 
≥ 15 IU/ml during follow-up in patients having undetectable HCV RNA at the 
end of treatment [8, 10]. Viral breakthrough was defined as a ≥10 U/ml increase 
from the nadir of HCV RNA or when HCV RNA ≥15 IU/ml after HCV-RNA was 
undetectable during the treatment [8, 10]. Non-response patients were defined as 
those with viral breakthrough, or post-treatment relapse, or with absence of initial 
decline of HCV RNA. 
 
4. Observations 
 
Clinical data were recorded manually from paper medical records and in 
CHUV's Soarian and Archimède databases: gender, date of birth, weight, height, 
date of treatment, treatment duration, treatment response, dose of DAAs, HCV 
genotype, FibroScan score stiffness, FibroScan score IQR, METAVIR score, 
Child-Pugh score, previous HCV therapies and number of cures, hepatocellular 
carcinoma (HCC), HCC treatment, transplantation, hemodialysis, HIV infection, 
HBV infection, IL28B rs12979860 genotype.  
Laboratory data were extracted from database Molis: HCV RNA, 
leucocytes, erythrocytes, hemoglobin, thrombocytes, prothrombin time, activated 
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partial thromboplastin time (aPTT), fibrinogen, creatinine, albumin, bilirubin 
(total and direct), alanine transaminase (ALT), aspartate transaminase (AST), 
alkaline phosphatase (ALP), gamma-glutamyltransferase (GGT), alpha-
fetoprotein (AFP), HCV mutation (NS5A).  
Initially, we had concentrations of drugs measured at the peak or in the 
middle of the dosing interval or at the trough. Assuming that trough level of drugs 
is the most informative, we included in our analysis only trough concentrations 
(i.e. those sampled at least 18 hours after drug administration).  
For the determination of the response to treatment, we followed HCV RNA 
levels before, during, and after treatment for each patient.  
 
5. Statistical Analysis 
 
To describe the data, we used the arithmetic means (± standard deviation 
or range) for numerical variables and fraction percentages for qualitative 
variables. The data of HCV RNA were transformed in logarithm of viral load.  
To compare the response and non-response groups, we used t-test (when 
the tested variable could be assumed to follow a normality assumption), Wilcoxon 
test (when the values could not be assumed to be normally distributed), and 
Fisher’s exact test (for categorical variables). A p-value lower than 0.05 was 
considered a statistically significant difference in standard tests. 
For the prediction of HCV infection relapse, we retained all variables for 
which a univariate test (Student, Wilcoxon, Fisher) reported a significant or a 
trend for association (p ≤ 0.1) and included them (forward stepwise approach) in 
a logistic regression model for multivariate analysis. Оdds ratios (OR) are 
presented with their 95% confidence intervals. 
We used the Pearson correlation coefficient (r) for correlation analysis.  
We generated histograms, dot plots, bar plots, and spaghetti plots to 
illustrate the results.  
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Statistical analyses were performed using the R version 3 and STATA 
version 15 software packages.  
 
Results 
 
1. Study population  
 
1.1. Population description 
 
Our initial data extraction from the laboratory database Molis (patients with 
3 or more available measurements of HCV RNA and liver function from 1 
January 2013 to 31 August 2017) produced data for 940 patients. From those, our 
selection of patients followed at the Service of Gastroenterology and Hepatology 
and treated between 1 January 2013 and 31 August 2017 with identified 197 
consecutive patients with clinical, histological, and laboratory documentation 
available. An additional combined search between the Molis extraction and the 
database for drug concentrations of the Division of Clinical Pharmacology 
identified 14 additional patients (followed in CHUV services other than 
Gastroenterology and Hepatology). Among these, available clinical information 
was found for 5 patients fulfilling our inclusion/exclusion criteria. Thus, we 
obtained complete data for 202 patients, who were eventually included in our 
analysis.  
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Figure 1: Schema of patient recruitment  
 
1.2. Clinical characteristics of study population 
 
The 202 patients included in the study were 144 men (71%) and 58 women 
(29%). Their mean age was 55.3±8.9 years (range 25-79). Among them, SVR was 
achieved by 193 patients (95.5%) irrespectively of the drug combination used. 
These 193 patients were included in the treatment-respondent group (137 men 
(71%), mean age 55.3±9.0 years), and the remaining 9 patients in the non-
response group (7 men (78%), mean age 55.6±8.0 years). All patients in the non-
response group actually achieved HCV RNA suppression under treatment but had 
a post-treatment relapse.  
940 patients with documented HCV viremia at 3 occasions 
(extraction from CHUV-Molis database)  
+ 14 additional patients 
followed in other CHUV 
departments but included in 
the plasma concentrations 
database (Division of Clinical 
Pharmacology)  
197 consecutive patients 
followed at the Service of 
Gastroenterology and 
Hepatology (CHUV), 
fulfilling inclusion/exclusion 
criteria and for whom clinical 
information was available 
5 patients fulfilling 
inclusion/exclusion criteria 
and for whom clinical 
information was available 
202 patients 
included 
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During our search for individual factors predicting treatment response, we 
did not find any significant differences between responders and non-responders 
in age, gender, BMI, HCV genotype, FibroScan score, METAVIR score, previous 
HCV therapy, hemodialysis, transplantation, HIV and HBV infection, and IL28B 
rs12979860 genotype. Conversely, in patients belonging to the non-response 
group, the rate of past HCC was higher than in the responders (56% and 10%, 
respectively, p=0.002). In addition, the distribution of Child-Pugh score differed 
significantly between both groups: 89% of patients in the response group had 
score A, 7% score B, and 4% score C, while in the non-response group they were 
67%, 22%, and 11%, respectively (p=0.045). Baseline clinical characteristics of 
the whole study population are shown in Table 1. Distributions of age, HCV 
genotype, and Child-Pugh score are represented in Figures 2, 3, and 4.  
 
  
               a                                                            b 
Figure 2: Distribution of age: a. response group, b. non-response group 
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            a                                                                  b    
Figure 3: Distribution of HCV genotype: a. response group, b. non-response group      
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            a                                                                  b 
Figure 4: Distribution of Child-Pugh score: a. response group, b. non-response group 
 
 
Table 1: Clinical characteristics of the study population (mean ± standard 
deviation or n (%)) 
Characteristic total responders non-responders p value 
Women : men  29% : 71% 29% : 71% 22% : 78% 1 
Age (years) 55.3±8.9  55.3±9.0  55.7±8.1  0.90 
Weight (kg) 77±15  77±15  77±9  0.94 
Height (cm) 173±10  173±10  174±8  0.73 
BMI (kg/m2) 26±4  26±4  26±4  0.96 
Treatment duration 
(weeks) 
16±6  16±6  20±6  0.09 
HCV genotype 1: 
 2: 
124 (61%) 
15 (8%) 
119 (62%) 
15 (8%) 
5 (56%) 
0 (0%) 
0.14 
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 3: 
 4: 
52 (26%) 
9 (5%) 
50 (26%) 
7 (4%) 
2 (22%) 
2 (22%) 
FibroScan stiffness 
score  
13.1±9.9 13.2±10.0 8.9±3.7 0.09 
FibroScan score IQR 2.1±1.9 2.1±1.8 2.2±2.8 0.97 
METAVIR score A 2±1 2±1 2±0 0.07 
METAVIR score F 3±1 3±1 3±1 0.12 
Child-Pugh score A: 
 B: 
 C: 
176 (88%) 
16 (8%) 
8 (4%) 
170 (89%) 
14 (7%) 
7 (4%) 
6 (67%) 
2 (22%) 
1 (11%) 
0.045 
Past history of HCC 25 (12%) 20 (10%) 5 (56%) 0.002 
Transplantation 11 (5%) 11 (6%) 0 (0%) 1 
Hemodialysis 1 (0.4%) 1 (0.5%) 0 (0%) 1 
HIV infection 15 (7%) 15 (8%) 0 (0%) 1 
HBV infection 45 (22%) 41 (21%) 4 (44%) 0.11 
IL28B rs12979860 
genotype CC: 
 CT: 
 
 3 (1.5%) 
12 (6%) 
 
 3 (2%) 
10 (5%) 
 
 0 (0%) 
2 (22%) 
0.12 
Previous HCV therapy  
Ribavirin  75 (37%) 71 (37%) 4 (44%) 0.72 
Peg-IFN 83 (41%) 78 (40%) 5 (56%) 0.53 
Boceprevir 2 (0.9%) 2 (1%) 0 (0%) 1 
Telaprevir 8 (3.9%) 8 (4%) 0 (0%) 1 
Sofosbuvir 2 (0.9%) 2 (1%) 0 (0%) 1 
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1.3 Laboratory characteristics of study population 
 
We analyzed the laboratory baseline characteristics of patients in both 
groups. We found significant differences between groups in erythrocytes level 
(p=0.049), prothrombin time (p=0.0002), creatinine level (p=0.005), ALP level 
(p=0.04), and bilirubin total level (p=0.02). All laboratory characteristics are 
described in Table 2.   
 
Table 2: Baseline laboratory characteristics of study population (mean ± 
standard deviation) 
Characteristic total response 
group 
non-response 
group 
p value 
Leucocytes 
G/l) 
5.7± 2.7 5.9±2.7 4.5±2.8 0.06 
Erythrocytes 
(T/l) 
4.2± 1.0 4.3±0.8 3.7±1.0 0.049 
Hemoglobin 
(g/l) 
131±28 132±28 118±28 0.06 
Thrombocytes 
(G/l) 
132±77 133±76 117±111 0.55 
aPTT (sec) 49±19 44±19 71±36 0.06 
Prothrombin 
time (%) 
77±28 81±28 50±30 0.0002 
Fibrinogen 
(g/l) 
1.5±0.8 1.5±0.8 1.0±1.0 0.59 
Creatinine 
(µmol/l) 
93±61 95±61 77±20 0.005 
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HCV RNA 
(log IU/ml) 
6.58±6.7 6.58±6.7 6.6±6.62 0.92 
Albumin (g/l) 38±6 39±6 34±7 0.07 
ALT (U/l) 93±71 88±71 153±163 0.18 
AST (U/l) 92±89 84±89 194±257 0.15 
ALP (U/l) 109±46 97±39 125±44 0.04 
GGT (U/l) 129±117 131±106 104±93 0.34 
AFP (ng/ml) 38±47 25±47 45±42 0.41 
Bilirubin total 
(mmol/l) 
27±39 23±39 60±56 0.02 
Bilirubin 
direct 
(mmol/l) 
13±21 13±21 22±20 0.19 
NS5A 
mutation 
0 (0%) 0 (0%) 0 (0%) 1 
 
2. Treatments 
 
 The median duration of antiviral treatment was 16±6 weeks for patients 
from the response group and 20±6 weeks for patients from the non-response group 
(p=0.09). All patients included in the study received sofosbuvir. This drug was 
combined with ledipasvir in most cases (50% of patients in the response group 
and 78% in the non-response group) and with daclatasvir, simeprevir, and 
ribavirin. In the response group, patients received a combination of 3 drugs: 
sofosbuvir + ledipasvir ± ribavirin or sofosbuvir + daclatasvir ± ribavirin. We did 
not find significant differences between the two groups in the type of drug used 
or in the drugs combination (Table 3 and 4).  
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Table 3: Treatment (by drug) 
Drug response group non-response group p value 
Sofosbuvir 193 (100%) 9 (100%) 1 
Daclatasvir 60 (31%) 2 (22%) 0.72 
Ledipasvir 111 (58%) 7 (78%) 0.31 
Ribavirin 57 (30%) 0 (0%) 0.06 
Simeprevir 2 (1%) 0 (0%) 1 
 
Table 4: Treatment (by drug combinations) 
Drug combination response group non-response group p value 
Sofosbuvir + 
simeprevir 
2 (1%) 0 (0%) 0.77 
Sofosbuvir + 
ribavirin 
20 (10%) 0 (0%) 
Sofosbuvir + 
ledipasvir 
96 (50%) 7 (78%) 
Sofosbuvir + 
ledipasvir + 
ribavirin 
15 (8%) 0 (0%) 
Sofosbuvir + 
daclatasvir 
38 (20%) 2 (22%) 
Sofosbuvir + 
daclatasvir + 
ribavirin 
22 (11%) 0 (0%) 
 
3. HCV RNA monitoring during treatment and viral kinetic model 
 
 Our dataset contained altogether 1771 HCV RNA determinations, among 
which 659 indicated detectable levels and 1112 undetectable viral load. The 
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median number of viral load determinations in our study patients was 8, with an 
interquartile range (IQR) of 7 to 10, a minimum of 3 and a maximum of 20 (mean 
± SD: 8.8 ± 3.2). Still the patients had only a median of 3 (IQR 2-4) detectable 
levels.  
 Patients from the non-response group had an average 10.6 determinations, 
i.e. some 2 determinations more than responders (p>0.05); moreover, they had 
expectedly a higher number of detectable levels (average 6.1 ± 0.9, versus 3.1 ± 
0.1 in the responder group).  
No virological breakthrough was recorded during the treatment period in 
any the 202 study patients. However, 9 patients (4.5%) experienced post-
treatment relapse.  
In most patients HCV-RNA levels were measured at baseline, at week 2, 
week 4, at the end of treatment, at 12 and at 24 weeks after treatment. The 
difference between both groups was not significant at baseline (p = 0.92) and at 
week 2, week 4, at the end of treatment (p>0.05).  
 In our analysis, we did not find any relationship between the rate of HCV 
RNA decrease under treatment and the treatment outcome. By definition, 
relapsing patients were characterized by post-treatment re-appearance and 
increase of viral load. We drew spaghetti plots for two patient groups, supported 
by a local regression fit (Figure 5).  
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Figure 5: Spaghetti plot of HCV-RNA level during the treatment (blue: response group; 
red: relapse group)  
 
 We found a positive correlation between HCV RNA and ALT (r = 0.47) 
and between HCV RNA and AST (r = 0.19) 
 
To describe the viral kinetics during treatment, most authors use a 
“biphasic” virologic response model. This model was published in 1998 for IFN-
based treatment [13]. It is described by the following biexponential function 
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In this model, HCV-RNA initially declines from pre-treatment plateau value (V0) 
with rate λ1  εc; thus the treatment is “potent” (ε  1), viral load declines with a 
maximum rate equal to c. This declining phase continues until the viral load 
reaches a value V1 that reflects the new equilibrium between the viral production 
and clearance under treatment given by: V1 = (1-ε) V0. Thus, for instance if ε = 
0.99, there will be a rapid decline of 2 log10 of viral load in the first 2 days.  
We tried to apply different models to described viral kinetics in study 
patients. First, we used a “monophasic model” 
V = V0 
.
 e 
- λt 
where V0 is the pre-treatment HCV RNA level and λ is the single coefficient 
of exponential decay.  
If we use this mathematical model, we obtain the parameter values:  
V = 4.949E+06, λ = 0.1588 (residual sum-of-squares: 5.02e+15=. The fitting is 
shown in Figure 6.  
 
 
Figure 6: Fit the exponential with model V = V0 . exp(-λt) 
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A model that apparently better describes the viral kinetics is a “double 
exponential model”, where 
log(V) = log(V0) 
.
 e 
– λt  
or 
V = V0 
. exp(exp(-λt)) 
 
If we use this mathematical model, we obtain the following coefficients:  
V0 = 6.9047, λ = 0.1066 (residual sum-of-squares: 366.4). The fitting is shown in 
Figure 7.  
 
 
Figure 7: Fit the exponential with model V = V0 . exp(exp(-λt)) 
 
Still in theory, both these models are less satisfactory than a biexponential 
model would be; however, the data precluded the adaptation of a biexponential 
model, because of the abundance of undetectable HCV RNA levels measured, 
leaving too few values to fit a biexponential equation; in particular, the early 
treatment period was poorly covered by measurement points. Neither was it 
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possible to fit a two-levels, hierarchical or mixed-effect model incorporating a 
between-patient variability on model parameters (V0, λ). Such a model would 
certainly have been conceptually quite correct, but the paucity of detectable HCV 
RNA levels precluded all our attempts for this analysis.  
 
4. Analysis of viral kinetics after end of treatment in relapse group  
 
All patients in relapse group experienced post-treatment relapse, and none 
shown primary non-response. We described the viral kinetics of these patients 
after end of treatment. The individual characteristics of these patients are shown 
in Table 5  
Table 5: Treatment duration and time of HCV relapse in treatment failure 
group 
Patient Treatment Treatment 
duration 
Time of HCV relapse 
after end of treatment 
Male, 45 years, 
genotype 1a 
Sofosbuvir + 
ledipasvir 
12 weeks 287 days 
Male, 57 years, 
genotype 1b 
Sofosbuvir + 
ledipasvir 
24 weeks 93 days 
Male, 50 years, 
genotype 3 
Sofosbuvir + 
daclatasvir 
24 weeks 91 days 
Male, 45 years, 
genotype 3 
Sofosbuvir + 
daclatasvir 
24 weeks 40 days 
Female, 56 years, 
genotype 4 
Sofosbuvir + 
ledipasvir 
24 weeks 84 days 
Male, 59 years, 
genotype 1a 
Sofosbuvir + 
ledipasvir 
12 weeks 89 days 
Male, 61 years 
genotype 1a 
Sofosbuvir + 
ledipasvir 
16 weeks  6 days 
Male, 52 years, 
genotype 1a 
Sofosbuvir + 
ledipasvir 
20 weeks 218 days 
Female, 71 years, 
genotype 4 
Sofosbuvir + 
ledipasvir 
12 weeks 3 days 
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We did not find any correlation between the duration of treatment and the 
time of relapse. There seemed to be 3 types of behavior: relapse immediately (3-
6 days after end of treatment), or about 80-90 days after end of treatment, or more 
than 6 months after treatment (Figure 8). 
 
 
Figure 8: Spaghetti plot of HCV RNA level after end of treatment in non-response 
group (green: treatment duration 12 or 16 weeks; black: treatment duration 20 or 24 
weeks)  
 
5. Liver function tests monitoring 
 
 Liver function monitoring (AST and ALT) was usually performed at the 
same time as HCV-RNA monitoring. At baseline we did not find any significant 
differences between groups in ALT (p = 0.18) or AST levels (p = 0.15). The levels 
of hepatic enzymes were not significantly different at weeks 2, 4 or at the end of 
treatment (p>0.05). 
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We did not find any relationship between the decrease rate of ALT and AST 
levels and treatment outcome. We drew spaghetti plots for two patient groups, 
supported by a local regression fit (Figure 9 and Figure 10). 
 
Figure 9: Spaghetti plot of ALT level during the treatment (blue, response group; red, 
non-response group)  
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Figure 10: Spaghetti plot of AST level during the treatment (blue, response group; red, 
non-response group)  
 
Figure 11 shows the viral and liver function tests over the monitoring 
course in a patient with SVR after 24 weeks of treatment and a patient with 
treatment relapse after 24 weeks of treatment.  
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a 
 
b.  
Figure 11: Monitoring profiles for HCV RNA (red), ALT (green), and AST (blue) of a 
representative patient (male, 53 years, genotype 1a) with SVR after 24 weeks of 
treatment with sofosbuvir + daclatasvir (a) and of a patient (male, 57 years, genotype 
1b) with relapse after 24 weeks of treatment with sofosbuvir + ledipasvir (b). 
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6. Analysis of drug concentration  
 
We analyzed the concentration values of sofosbuvir, its metabolite 
GS331007, daclatasvir, and ledipasvir. We did not consider the concentrations of 
drugs measured at the peak or in the middle of the dosing interval. Assuming that 
the trough levels (measured at the end of the dosing interval) were the most 
informative ones, we had drug 95 concentration values for 29 patients (85 values 
for 27 patients in the response group and only 8 values for 2 patients in the non-
response group).  
The mean concentration of drug in patients was 579±502 ng/ml for 
GS331007, 640±519 ng/ml for daclatasvir, and 345±212 ng/ml for ledipasvir. In 
the response group, the mean concentration was 596±521 ng/ml for GS331007, 
652±528 ng/ml for daclatasvir, and 347±215 ng/ml for ledipasvir. In the non-
response group, the mean concentration was 404±102 ng/ml for GS331007, 
376±91 ng/ml for daclatasvir. Taken individually as if they were independent 
points, these valued would reveal significant differences between groups for 
GS331007 (p=0.006) and daclatasvir (p=0.03). Still a more correct analysis taking 
into account the clustering of concentration values measured on several occasions 
in the same patients failed to show significant differences. The concentration 
values are represented in Figure 12 and 13, suggesting graphically a trend for 
lower levels in non-responders.  
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Figure 12: Concentration of GS331007 in non-response and response patients  
 
Figure 13: Concentration of daclatasvir in relapse and response patients  
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7. Prediction of the response to treatment 
 
We used a logistic regression model to predict the response to treatment. 
We constructed a predictive model using individual covariates (all variables for 
which a univariate test (Student, Wilcoxon, Fisher) reported a significant change 
(p ≤0.1) 
The multivariate analysis showed that only past HCC (p<0.0001; OR, 
0.06), HBV infection (p=0.038; OR, 0.19), and IL28B rs12979860 genotype CT 
(p=0.02; OR, 0.09) were independent predictors of treatment failure (Table 6).  
 
Table 6: Predictors of the treatment response  
Characteristic Univariate analysis  Multivariate analysis 
p value OR (95% CI) p value 
Past HCC 0.002 0.06 (0.01-0.28) <0.0001 
HBV infection 0.11 0.19 (0.04-0.92) 0.038 
IL28B rs12979860 
genotype CT 
0.12 0.09 (0.01-0.69) 0.02 
 
It should be noted that neither hepatic tests, nor drug concentration were 
predictors of treatment response, either independently or added over the above 
variables into the model.  
 
 
Discussion 
 
 The primary goal of HCV therapy is to achieve SVR, defined as 
undetectable HCV RNA 12 weeks (SVR12) or 24 weeks (SVR24) after treatment 
completion [8, 11]. The modern DAA therapy is associated with high SVR rate 
(more than 90%). In our study, 95.5% of patients had achieved the SVR.  
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The characteristics of our population do not markedly differ from large 
cohorts previously described, i.e. the most frequent HCV genotype is 1 (61%), 
followed by genotypes 3, 4, and 2; the most frequent Child-Pugh score is A (88%).  
In our study, the non-response group is made only of patients with post-
treatment relapse. We did not observe patients with immediate non-response or 
virological breakthrough. According to literature, the rate of virological 
breakthrough during DAA therapy is very low, about 1-2% [14], and most of non-
response cases are explained by post-treatment relapse. 
Patients in response and non-response groups had similar clinical 
characteristics, except for the rate of history of HCC which was significantly 
higher in the non-response group (56% vs 10%, p=0.002) and a higher prevalence 
of Child-Pugh scores B and C in non-response patients (33% vs 11%, p=0.045). 
We did not find statistically significant differences between both groups at 
baseline in main laboratory parameters such as platelet count, aPTT, AST, ALT, 
albumin, GGT, AFP, and HCV RNA viral load. At the same time, the level of 
total bilirubin, ALP, creatinine, and erythrocytes was significantly higher in non-
response patients (all p <0.05), in relation with the worse level of liver function 
captured by the Child score and HCC status.  
With regard to predictive factors associated with non-response to therapy, 
various host and viral variables (e.g., gender, age, race, BMI, insulin resistance, 
advanced fibrosis stage, HCV genotype, presence of VIH, and viral load) had 
been well identified and were associated with non-response to Peg-IFN based 
therapies [15-17]. In patients treated with DAAs, the possible predictors of non-
response were older age, cirrhosis, especially Child–Pugh class B and C, low 
platelet count, HCV genotypes 3 or 1a, elevated serum HCV RNA, prior hepatitis 
C treatment failure, poor drug adherence, and premature drug discontinuation [18-
22].  
Multivariate analysis showed that past HCC, HBV infection, and IL28B 
rs12979860 genotype CT are independent predictors of treatment failure. The 
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IL28B gene is involved in the immune response to certain viruses, including 
hepatitis C. People with the CC genotype have a stronger immune response to 
HCV infection than people with the CT or TT genotypes. It was shown in earlier 
studies that patients with the CC genotype are two to three times more likely to 
be cured by Peg-IFN and RBV, regardless of race or HIV status [23]. In the study 
of Prenner SB et al., the presence of active HCC at the initiation of HCV therapy 
is significantly associated with DAA treatment failure [24]. Sugiura A et al. 
showed that patients with history of HCC were independently associated with 
DAA treatment failure (OR, 3.56) [25]. Regarding on HBV infection status, Yek 
C et al. found that this infection did not have an impact on DAAs treatment 
response [26]. In other studies, HBV co-infection (past or current) also did not 
contribute to HCV therapy outcome [27].  
All patients in our study received sofosbuvir. This drug was combined with 
ledipasvir in most of cases. We did not find significant differences between both 
groups in the type of drug or drugs combination used.  
 The initial goal of our study was to analyze whether HCV RNA level 
profiles during DAA therapy would predict the final treatment outcome. 
Consistent with already published data on rapid decrease of viral kinetics under 
DAA therapy, we did not find any relationship between viral kinetics and 
treatment response. The HCV RNA level at baseline, at week 2, week 4 and at the 
end of treatment failed to predict treatment response (p>0.05). Our results are I 
line with other studies. For example, a recent analysis by Fourati S et al. found 
that HCV RNA levels at the end of treatment could not differentiate between 
patients who achieving SVR or not [28]. In another study published in 2017, 
monitoring by HCV RNA during treatment with DAAs had only a limited 
predictive value for SVR, and the authors did not observe significant differences 
between response and non-response patients at 2 and 4 weeks after the start of 
treatment [29]. Furthermore, low levels of HCV RNA during treatment or at the 
end of treatment do not predict a relapse [30, 31], and this represents reasons for 
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simplification of the monitoring strategy. Similarly, our results do not indicate 
any usefulness of checking the decay of HCV RNA levels during treatment, as 
viral suppression seems to be guaranteed in all cases.  
International clinical guidelines did not support either the monitoring of 
hepatic tests like ALT or AST during the HCV therapy. Our results essentially 
confirm this view. We did not find significant differences between response and 
non-response groups at baseline, at 2 and 4 weeks after the start of treatment, nor 
at the end of treatment. 
In our study we measured the trough concentration of sofosbuvir, its 
metabolite GS331007, daclatasvir, and ledipasvir. We found that patients from 
non-response group had a trend for lower concentration of GS331007 and 
daclatasvir. We did not find a significant correlation between DAAs plasma 
concentration and HCV viral load kinetics during treatment. However, in some 
studies such correlations were reported [32, 33]. 
Our study has several limitations. First, it is a retrospective and 
observational analysis. Secondly, we had a limited number of detectable HCV 
RNA measurements during the treatment, which does not allow to describe the 
viral kinetics with an appropriate virologic response model. Moreover, we had 
very limited data about drug concentrations, especially for patients from the non-
response group. It is thus impossible to express any strong statement about the 
potential usefulness of concentration monitoring during treatment with DAAs. 
There is only a slight signal suggesting that it might have some prognostic interest 
regarding SVR achievement, still warranting further confirmation.  
In conclusion, our results do not support the regular monitoring of HCV 
RNA, AST, and ALT during treatment. Our results are thus essentially consistent 
with the last EASL recommendations on treatment of hepatitis C, i.e. that HCV 
RNA level are to be measured no three occasions only, i.e. at baseline and 12 or 
24 weeks after the end of therapy (to assess SVR12 or SVR24, respectively) [8]. 
A potential role for drug concentration monitoring deserves further investigation.  
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hepatitis C in Switzerland: trends in notifications, 1988–2015. Swiss Med 
Wkly. 2018;148:w14619.  
5. Petruzziello A, Marigliano S, Loquercio G, et al. Global epidemiology of 
hepatitis C virus infection: An up-date of the distribution and circulation of 
hepatitis C virus genotypes. World J Gastroenterology. 2016; 22(34):7824–
40. 
6. World Health Organization. Hepatitis C. Fact Sheet No. 164 (updated 18 
July 2018). https://www.who.int/news-room/fact-sheets/detail/hepatitis-c 
 35 
7. Pawlotsky JM, Feld JJ, Zeuzem S, Hoofnagle JH. From non-A, non-B 
hepatitis to hepatitis C virus cure. J Hepatol. 2015; 62:S87-S99. 
8. European Association for the Study of the Liver. EASL Recommendations 
on Treatment of Hepatitis C, 2018. Journal of Hepatology. 2018; 
69(2):461-511.   
9. Lens S, Marino Z, Forns X. Efficacy of new direct acting antivirals in 
transplant recipients and patients with advanced disease. Digestive and 
liver disease: official journal of the Italian Society of Gastroenterology and 
the Italian Association for the Study of the Liver. 2014; 46 Suppl 5:S197–
205. 
10. European Association for the Study of the Liver. EASL Recommendations 
on Treatment of Hepatitis C, 2016. Journal of Hepatology. 2017; 
66(1):153-94.  
11. American Association for the Study of Liver Diseases and the Infectious 
Diseases Society of America. HCV Guidance: Recommendations for 
Testing, Managing, and Treating Hepatitis C, 2018.  
12. Sidharthan S, Kohli A, Sims Z, et al. Utility of hepatitis C viral load 
monitoring on direct-acting antiviral therapy. Clin Infect. Dis 2015; 
60:1743–51. 
13. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo 
and the antiviral efficacy of interferon-alpha therapy. Science. 1998 
;282(5386):103-7. 
14. Elberry MH, Darwish HE, Mousa SA.  Hepatitis C virus management: 
potential impact of nanotechnology. Virology Journal 2017; 14:88.  
15. Afdhal NH, McHutchison JG, Zeuzem S, et al. Hepatitis C 
pharmacogenetics: state of the art in 2010. Hepatology. 2011; 53:336–45.  
16. Hadziyannis SJ, Sette H, Morgan TR, et al. Peginterferon alpha 2a and 
ribavirin combination therapy in chronic hepatitis C: a randomized study 
 36 
of treatment duration and ribavirin dose. Ann Intern Med. 2004; 140:346–
55.  
17. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: 
efficacy, side effects, and complications. Gut. 2006; 55:1350–59. 
18. Reid M, Price JC, Tien PC. Hepatitis C virus infection in the older 
patient. Infect Dis Clin N Am. 2017; 31:827–38. 
19. Saab S, Park SH, Mizokami M, et al. Safety and efficacy of 
ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects 
aged 65 year or older. Hepatology. 2016;63(4):1112–19.  
20. Ferenci P, Kozbial K, Mandorfer M, Hofer H. HCV targeting of patients 
with cirrhosis. J Hepatol. 2015; 63:1015–22. 
21. Ahmed OA, Ahmed, Elsebaey M, Fouad MH, et al. Outcomes and 
predictors of treatment response with sofosbuvir plus daclatasvir with or 
without ribavirin in Egyptian patients with genotype 4 hepatitis C virus 
infection. Infect Drug Resist. 2018; 11: 441–45. 
22. Benítez-Gutiérrez L, Barreiro P, Labarga P, et al. Prevention and 
management of treatment failure to new oral hepatitis C drugs. Expert Opin 
Pharmacother. 2016; 17(9):1215-23.  
23. Berger CT, Kim AY. IL28B polymorphisms as a pre-treatment predictor of 
response to HCV treatment. Infect Dis Clin North Am. 2012; 26(4): 863–
77. 
24. Prenner SB, VanWagner LB, Flamm SL, et al. Hepatocellular carcinoma 
decreases the chance of successful hepatitis C virus therapy with direct-
acting antivirals. J Hepatol. 2017; 66(6): 1173–81. 
25. Sugiura A, Joshita S, Umemur T, et al. Past history of hepatocellular 
carcinoma is an independent risk factor of treatment failure in patients with 
chronic hepatitis C virus infection receiving direct‐acting antivirals. Journal 
of Viral Hepatitis. 2018 Jul 25. [Epub ahead of print]. 
 37 
26. Yek C, Flor C, Marshall J, et al. Effectiveness of direct-acting antiviral 
therapy for hepatitis C in difficult-to-treat patients in a safety-net health 
system: a retrospective cohort study. BMC Med. 2017; 15: 204. 
27. Gidding HF, Law MG, Amin J, et al. Predictors of deferral of treatment for 
hepatitis C infection in Australian clinics. Med J Aust 2011; 194 (8): 398-
402. 
28. Fourati S, Guedj J, Chevaliez S, et al. Viral kinetics analysis and virological 
characterization of treatment failures in patients with chronic hepatitis C 
treated with sofosbuvir and an NS5A inhibitor. Aliment Pharmacol Ther. 
2018; 47(5):665-73.  
29. Loggi E, Galli S, Vitale G, et al. Monitoring the treatment of hepatitis C 
with directly acting antivirals by serological and molecular methods. PLoS 
One. 2017; 12(11): e0187755. 
30. Rockstroh JK, Feld JJ, Chevaliez S, et al. HCV core antigen as an alternate 
test to HCV RNA for assessment of virologic responses to all-oral, 
interferon-free treatment in HCV genotype 1 infected patients. Journal of 
virological methods. 2017;c245:14–8.  
31. Sarrazin C, Wedemeyer H, Cloherty G,cet al. Importance of very early 
HCV RNA kinetics for prediction of treatment outcome of highly effective 
all oral direct acting antiviral combination therapy. Journal of virological 
methods. 2015; 214:29–32. 
32. Virlogeux V, Choupeaux L, Pradat P, et al. Sofosbuvir plus daclatasvir with 
or without ribavirin for chronic hepatitis C infection: Impact of drug 
concentration on viral load decay. Dig Liver Dis. 2016; 48(11):1351-56. 
33. de Kanter CT, Buti M, DeMasi R, et al. Ribavirin concentration determines 
treatment success of first-generation DAA-based chronic HCV therapy. 
Antivir Ther. 2016;21(2):153-9.  
 
